Pancreatic cancer is one of the faster spreading cancers; only about 4% of patients can expect to survive five years after their diagnosis. Each year, about 44,000 new cases are diagnosed in the U.S., and 37,000 people die of the disease.
The pancreas contains two types of glands: exocrine glands that produce enzymes that break down fats and proteins, and endocrine glands that make hormones like insulin that regulate sugar in the blood. Jobs died of tumors originating in the endocrine glands, which are among the rarer forms of pancreatic cancer.
IN MEMORIAM: Technology’s Great Reinventor: Steve Jobs (1955-2011)
In 2004, Jobs underwent surgery to remove the cancer from his pancreas. In 2009, after taking another leave of absence from Apple, Jobs had a liver transplant in an effort to retain as much of his organ function as possible after his cancer had spread beyond the pancreas. In January, he took a third leave from the company before resigning as CEO in August.
“I have always said if there ever came a day when I could no longer meet my duties and expectations as Apple’s CEO, I would be the first to let you know,” Jobs wrote in a letter to the Apple board of directors on August 24. “Unfortunately, that day has come.”
According to experts, Jobs’ was an uphill medical battle. “He not only had cancer, he was battling the immune suppression after the liver transplant,” Dr. Timothy Donahue of the UCLA Center for Pancreatic Disease in Los Angeles, who had not treated Jobs, told MSNBC.com. He noted that most patients who receive liver transplants survive about two years after the surgery.
Standard treatments for pancreatic cancer include the common tumor-fighting strategies — surgery, chemotherapy, radiation and, most recently, targeted anticancer drugs that may slightly extend patients’ lives. In 2005, the Food and Drug Administration approved erlotinib, a drug that specifically targets growth factors found on cancer cells, for the treatment of patients with advanced pancreatic cancer who are receiving chemotherapy. The drug has been shown in trials to improve overall survival by 23% after a year when added to routine chemotherapy. The tumors in patients being treated with erlotinib and chemo also develop more slowly than those in patients receiving chemotherapy alone.
Blogger Comment
Facebook Comment